Market Insight: Regulus Therapeutics Inc (RGLS)’s Notable Drop, Closing at 2.09

For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.

In the latest session, Regulus Therapeutics Inc (NASDAQ: RGLS) closed at $2.09 down -5.43% from its previous closing price of $2.21. In other words, the price has decreased by -$5.43 from its previous closing price. On the day, 0.54 million shares were traded. RGLS stock price reached its highest trading level at $2.28 during the session, while it also had its lowest trading level at $2.03.

Ratios:

For a deeper understanding of Regulus Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.32 and its Current Ratio is at 17.32. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on March 18, 2024, initiated with a Outperform rating and assigned the stock a target price of $6.

On March 28, 2018, B. Riley FBR Inc. started tracking the stock assigning a Neutral rating and target price of $1.

On January 05, 2018, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $2.Leerink Partners initiated its Outperform rating on January 05, 2018, with a $2 target price.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 18 ’24 when Hagan Joseph P sold 14,580 shares for $1.19 per share. The transaction valued at 17,359 led to the insider holds 57,112 shares of the business.

CALSADA CRISPINA sold 5,468 shares of RGLS for $6,510 on Jan 18 ’24. The Chief Financial Officer now owns 5,782 shares after completing the transaction at $1.19 per share. On Jan 18 ’24, another insider, Aker Christopher Ray, who serves as the Sr. VP & General Counsel of the company, sold 5,468 shares for $1.19 each. As a result, the insider received 6,510 and left with 10,056 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGLS now has a Market Capitalization of 136823728 and an Enterprise Value of 124018208.

Stock Price History:

The Beta on a monthly basis for RGLS is 1.64, which has changed by 0.4413793 over the last 52 weeks, in comparison to a change of 0.2704494 over the same period for the S&P500. Over the past 52 weeks, RGLS has reached a high of $3.79, while it has fallen to a 52-week low of $1.08. The 50-Day Moving Average of the stock is -11.33%, while the 200-Day Moving Average is calculated to be 28.79%.

Shares Statistics:

For the past three months, RGLS has traded an average of 3.15M shares per day and 577210 over the past ten days. A total of 65.47M shares are outstanding, with a floating share count of 57.42M. Insiders hold about 12.29% of the company’s shares, while institutions hold 28.25% stake in the company. Shares short for RGLS as of 1714435200 were 4208784 with a Short Ratio of 1.34, compared to 1711584000 on 5423646. Therefore, it implies a Short% of Shares Outstanding of 4208784 and a Short% of Float of 8.17.

Most Popular

[the_ad id="945"]